Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data from orthotopic U-87 MG xenograft mouse models

ABSTRACT: Glioblastoma (GBM) is classified as World Health Organization grade IV tumors of the central nervous system, and it is the most malignant form of glioma. The current GBM therapies could not completely eliminate the tumor mass and the occurrence of therapeutic resistance of surviving GBM cells is considered as an obstacle to be overcome. We used microarrays to detail the global program of gene expression underlying development of radioresistance of GBM and identified a variety of genes whose expressions were regulated during this process.

ORGANISM(S): Homo sapiens

PROVIDER: GSE117126 | GEO | 2018/07/17

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Expression data from orthotopic U-87 MG xenograft mouse models

Project description:Expression data from orthotopic U-87 MG xenograft mouse models

| PRJNA481241 | ENA

A Zebrafish-Based Orthotopic Glioblastoma Xenograft Model for Preclinical Drug Screening and Clinical Drug Sensitivity Prediction

Project description:A reliable animal model that can mimic the GBM intracranial infiltration and Blood-brain barrier (BBB) interaction is necessary for effective therapeutics development. Here, we report a zebrafish-based orthotopic GBM xenograft model, in which GBM cells from different species and even patients, can robustly propagate and faithfully reproduce their histological characteristics. Single-cell RNA-seq indicates a transcriptomic adaption of GBM xenografts to infiltrative phenotype within the zebrafish brains. We also provide evidence that the BBB in zebrafish larva is molecularly and functionally intact and can interact with GBM cells in similar ways as in mammals, which together enables this model to accurately identify BBB penetrating drugs. Using GBM patients’ samples, we further generate zebrafish patient-derived orthotopic xenografts (z-PDOX) and proof-of-concept experiments indicate the short-term temozolomide response in z-PDOX can predict the long-term prognosis of corresponding GBM patients. These together illustrate the value of zebrafish GBM model in drug discovery and precision medicine.

2022-04-12 | GSE147526 | GEO

Patient specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ (CGH)

Project description:Frequent discrepancies between preclinical and clinical results of anti-cancer agents demand a reliable translational platform that can precisely recapitulate the biology of human cancers. Another critical unmet need is the ability to predict therapeutic responses for individual patients. Toward this goal, we have established a library of orthotopic glioblastoma (GBM) xenograft models using surgical samples of GBM patients. These patient-specific GBM xenograft tumors recapitulate histopathological properties and maintain genomic characteristics of parental GBMs in situ. Furthermore, in vivo irradiation, chemotherapy, and targeted therapy of these xenograft tumors mimic the treatment response of parental GBMs. We also found that establishment of orthotopic xenograft models portends poor prognosis of GBM patients and identified the gene signatures and pathways signatures associated with the clinical aggressiveness of GBMs. Together, the patient-specific orthotopic GBM xenograft library represent the preclinically and clinically valuable “patient tumor’s phenocopy” that represents molecular and functional heterogeneity of GBMs. aCGH experiments were performed for a human glioblastoma tissue (sample ID: PC-NS08-559) and the matching xenograft tumor tissue using the Agilent Human Whole Genome CGH 244K microarray according to manufacturer's protocol (2-color).

2013-01-18 | E-GEOD-42577 | biostudies-arrayexpress

Patient specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ (gene expression)

Project description:Frequent discrepancies between preclinical and clinical results of anti-cancer agents demand a reliable translational platform that can precisely recapitulate the biology of human cancers. Another critical unmet need is the ability to predict therapeutic responses for individual patients. Toward this goal, we have established a library of orthotopic glioblastoma (GBM) xenograft models using surgical samples of GBM patients. These patient-specific GBM xenograft tumors recapitulate histopathological properties and maintain genomic characteristics of parental GBMs in situ. Furthermore, in vivo irradiation, chemotherapy, and targeted therapy of these xenograft tumors mimic the treatment response of parental GBMs. We also found that establishment of orthotopic xenograft models portends poor prognosis of GBM patients and identified the gene signatures and pathways signatures associated with the clinical aggressiveness of GBMs. Together, the patient-specific orthotopic GBM xenograft library represent the preclinically and clinically valuable “patient tumor’s phenocopy” that represents molecular and functional heterogeneity of GBMs. Gene expression profiling experiments were conducted for 58 human glioblastoma samples using Affymetrix Human Gene 1.0 ST arrays according to manufacturer's protocol.

2013-01-18 | E-GEOD-42669 | biostudies-arrayexpress

Glioblastoma Orthotopic Xenograft Transcriptome

Project description:Transcriptional profiling of glioblastoma orthotopic xenografts Descriptive experiment, comparison of 39 glioblastoma tumors as orthotopic xenografts

| S-ECPF-GEOD-38814 | biostudies-other

Establishment of radioresistant U87MG glioblastoma cell line

Project description:To explore factors contributing to radioresistance in GBM, we established GBM radioresistant cell line using U87MG human GBM cells.

2022-06-29 | GSE207002 | GEO

Patient specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ (CGH)

2013-01-18 | GSE42577 | GEO

Patient specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ (gene expression)

2013-01-18 | GSE42669 | GEO

Antitumor effects of intravenous natural killer cell infusion in an orthotopic glioblastoma xenograft murine model and gene expression profile analysis

Project description:Despite standard multimodality treatments, including maximal safe resection, te-mozolomide, radiotherapy, and tumor-treating fields, patients with glioblastoma (GBM) face dismal prognosis. Natural killer cell (NKC)-based immunotherapy appears to be a promising approach to treat GBM. We previously reported a novel technique to derive ex vivo-expanded highly activated NKCs from human peripheral blood mononuclear cells, which exhibited no-table antitumor effects against GBM cells. In this study, we performed preclinical evaluation of these NKCs in an in vivo orthotopic xenograft murine model, which was established by sub-cutaneously implanting U87MG cells in nonobese diabetes/severe combined immunodefi-ciency/IL2rγ null (NOG) mice. In this model, administering NKCs via the retro-orbital sinus prolonged the overall survival of NOG mice, indirectly indicating the growth inhibitory ef-fects of NKCs. In addition, we performed a comprehensive analysis of differentially ex-pressed genes using microarray, focusing on the expression of NKC activating receptor lig-ands, NKC inhibitory receptor ligands, chemokines, and chemokine receptors, between intra-cranial tumors treated with NKCs and non-treated intracranial tumors. We also performed differential gene expression analysis between the internal and external layers of intracranial tumors. Our findings provide crucial insights into NKC-based immunotherapy for patients with GBM.

2023-11-27 | GSE248352 | GEO

polyA mRNA RNA-seq from U-87 MG (ENCSR000BYO)

Project description:RNA-seq on U87 greater than 200bp polyA+ For data usage terms and conditions, please refer to http://www.genome.gov/27528022 and http://www.genome.gov/Pages/Research/ENCODE/ENCODE_Data_Use_Policy_for_External_Users_03-07-14.pdf

2016-12-07 | GSE90176 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data